FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab

An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.